Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Ethris Announces Research Based Alliance on SNIM® Modified RNA with Shire

Published: Monday, January 07, 2013
Last Updated: Monday, January 07, 2013
Bookmark and Share
Ethris GmbH and Shire announce the initiation of a research based alliance focused on the development and commercialization of novel RNA-based therapeutics.

Many devastating human diseases are the result of an inability of the body’s cells to make specific proteins that have an essential function for the whole body. The replacement of proteins with normally functioning ones provides a potential approach to treat multiple devastating diseases. Ribonucleic acids (RNAs) that encode for such proteins have been the focus of much biopharmaceutical research and development, however, RNA’s inherent instability and immunogenicity has proven to be a significant hurdle in the past.

Based in Munich, Germany, ethris and its co-founders – Dr. Carsten Rudolph and Prof. Christian Plank, have developed a novel RNA modification technology that creates Stable and Non-Immunogenic Messenger RNA (SNIM®-RNA) molecules that are ideally suited for use in protein replacement therapies to treat monogenic genetic diseases.

“We are delighted to extend our existing collaboration with Shire that may bring novel therapeutics to patients suffering diseases with significant unmet medical need. We aim to provide significant numbers of patients with new therapeutic alternatives that may provide a lasting solution to their disease,” stated Dr. Carsten Rudolph, CEO and co-founder of ethris.

“As a leader in the treatment of rare diseases, we are pleased to be working with ethris to develop SNIM®-RNA based therapies, with the objective of developing new treatment options to patients suffering from these rare disorders” said Dr. Philip J. Vickers, Global Head of Research and Development, Shire Human Genetic Therapies.

“With Shire we have a partnership based on a shared appreciation of the importance of our SNIM® technology. Under this partnership, we are aiming to develop an RNA modification and delivery technology that efficiently results in protein replacement in relevant cellular populations, providing hope to patients suffering from genetic diseases which have devastating clinical outcomes” commented Prof. Christian Plank CSO and co-founder of ethris.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More Than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Genetic Defences of Bacteria Don’t Aid Antibiotic Resistance
Genetic responses to the stresses caused by antibiotics don’t help bacteria to evolve a resistance to the medications, according to a new study by Oxford University researchers.
Detecting HIV Diagnostic Antibodies with DNA Nanomachines
New research may revolutionize the slow, cumbersome and expensive process of detecting the antibodies that can help with the diagnosis of infectious and auto-immune diseases such as rheumatoid arthritis and HIV.
Snapshot Turns T Cell Immunology on its Head
New research may have implications for 1 diabetes sufferers.
Tolerant Immune System Increases Cancer Risk
Researchers have found that individuals with high immunoCRIT ratios may have an increased risk of developing certain cancers.
Developing a Gel that Mimics Human Breast for Cancer Research
Scientists at the Universities of Manchester and Nottingham have been funded to develop a gel that will match many of the biological structures of human breast tissue, to advance cancer research and reduce animal testing.
Cell's Waste Disposal System Regulates Body Clock Proteins
New way to identify interacting proteins could identify potential drug targets.
New Approach to Treating Heparin-induced Blood Disorder
A potential treatment for a serious clotting condition that can strike patients who receive heparin to treat or prevent blood clots may lie within reach by elucidating the structure of the protein complex at its root.
Horse Illness Shares Signs of Human Disease
Horses with a rare nerve condition have similar signs of disease as people with conditions such as Alzheimer’s, a study has found.
How a Molecular Motor Untangles Protein
Diseases such as Alzheimer’s, Parkinson’s and prion diseases, all involve “tangled” proteins.
Compound Doubles Up On Cancer Detection
Researchers have found that tagging a pair of markers found almost exclusively on a common brain cancer yields a cancer signal that is both more obvious and more specific to cancer.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos